From Stigmatized Neglect to Active EngagementClark M.R.a,c · Treisman G.J.a–d
Departments of aPsychiatry and Behavioral Sciences and bMedicine, The Johns Hopkins University School of Medicine, and cChronic Pain Treatment Program and dAIDS Psychiatry Service, The Johns Hopkins Medical Institutions, Baltimore, Md., USA
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Chronic pain and substance abuse are common problems. Each entity represents a significant and independent burden to the patients affected by them, the healthcare system caring for them, and society at large supporting them. If the two problems occur together, all of these burdens and their consequences are magnified. Traditional treatments fail a substantial percentage of even the most straightforward cases. Clearly, new approaches are required for the most complex of cases. Success is possible only if multiple disciplines provide integrated care that incorporates all of the principles of substance abuse and chronic pain rehabilitation treatment into one package. While experience provides the foundation for implementing these programs, research that documents the methods behind successful outcomes will be needed to sustain support for them.
© 2011 S. Karger AG, Basel
Cohen MJ Jasser S Herron PD Margolis CG: Ethical perspectives: opioid treatment of chronic pain in the context of addiction. Clin J Pain 2002; 18: ((suppl)) S99-S107
Drug Enforcement AdministrationA joint statement from 21 health organizations and the Drug Enforcement Administration. Promoting pain relief and preventing abuse of pain medications: a critical balancing act. J Pain Symptom Manage 2002; 24: 147
Nicholson B: Responsible prescribing of opioids for the management of chronic pain. Drugs 2003; 63: 17-32
Gilson AM Joranson DE: US policies relevant to the prescribing of opioid analgesics for the treatment of pain in patients with addictive disease. Clin J Pain 2002; 18: ((suppl)) S91-S98
Rosenblum A Joseph H Fong C Kipnis S Cleland C Portenoy RK: Prevalence and characteristics of chronic pain among chemically dependent patients in methadone maintenance and residential treatment facilities. JAMA 2003; 289: 2370-2378
Peles E Schreiber S Gordon J Adelson M: Significantly higher methadone dose for methadone maintenance treatment (MMT) patients with chronic pain. Pain 2005; 113: 340-346
Ready LB Sarkis E Turner JA: Self-reported vs actual use of medications in chronic pain patients. Pain 1982; 12: 285-294
Fishbain DA Cutler RB Rosomoff HL Rosomoff RS: Validity of self-reported drug use in chronic pain patients. Clin J Pain 1999; 15: 184-191
Currie SR Hodgins DC Crabtree A Jacobi J Armstrong SJ: Outcome from integrated pain management treatment for recovering substance abusers. Pain 2003; 4: 91-100
Scimeca MM Savage SR Portenoy R Lowinson J: Treatment of pain in methadone-maintained patients. Mt Sinai J Med 2000; 67: 412-422
Ziegler PP: Addiction and the treatment of pain. Subst Use Misuse 2005; 40: 1945-1954; 2043-2048
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.